Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer

References

• Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, et al. 2011. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecologic Oncology 120:23–28.
   PubMed Web of Science ®Google Scholar
• Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. 2009. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecologic Oncology 112:16–21.
   PubMed Web of Science ®Google Scholar
• Anuradha S, Webb PM, Blomfield P, Brand AH, Friedlander M, Leung Y, et al. 2014. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. The Medical Journal of Australia 201:283–288.
   PubMed Web of Science ®Google Scholar
• Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, et al. 2012. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecologic Oncology 125:25–30.
   PubMed Web of Science ®Google Scholar
• Birim O, Maat AP, Kappetein AP, Van Meerbeeck JP, Damhuis RA, Bogers AJ. 2003. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery 23:30–34.
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. 1994. Validation of a combined comorbidity index. Journal of Clinical Epidemiology 47:1245–1251.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, Mackenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40:373–383.
   PubMedGoogle Scholar
• Chereau E, Ballester M, Selle F, Rouzier R, Darai E. 2011. Ovarian cancer in the elderly: impact of surgery on morbidity and survival. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 37:537–542.
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. 2009. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecologic Oncology 114:26–31.
   PubMed Web of Science ®Google Scholar
• Clark RM, Lee MS, Alejandro Rauh-Hain J, Hall T, Boruta DM, Del Carmen MG, et al. 2015. Surgical Apgar Score and prediction of morbidity in women undergoing hysterectomy for malignancy. Gynecologic Oncology 136:516–520.
   PubMed Web of Science ®Google Scholar
• Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, et al. 2009. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. European Journal of Surgical Oncology 35:135–143.
   PubMed Web of Science ®Google Scholar
• Das N, Talaat AS, Naik R, Lopes AD, Godfrey KA, Hatem MH, et al. 2006. Risk adjusted surgical audit in gynaecological oncology: P-POSSUM does not predict outcome. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 32:1135–1138.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, RAY-Coquard I, Pfisterer J. 2009. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234–1244.
   PubMed Web of Science ®Google Scholar
• Eisenkop SM, Friedman RL, Wang HJ. 1998. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecologic Oncology 69:103–108.
   PubMed Web of Science ®Google Scholar
• Elit L, Bondy SJ, Chen Z, Paszat L. 2007. A tale of two time periods: ovarian cancer trends in Ontario. Current Oncology (Toronto, Ont.) 14:57–60.
   PubMedGoogle Scholar
• Fairfield KM, Murray K, Lucas FL, Wierman HR, Earle CC, Trimble EL, et al. 2011. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. Journal of Clinical Oncology 29:3921–3926.
   PubMed Web of Science ®Google Scholar
• Fried L, Bernardini J, Piraino B. 2001. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation 37:337–342.
   PubMed Web of Science ®Google Scholar
• Grann AF, Thomsen RW, Jacobsen JB, Norgaard M, Blaakaer J, Sogaard M. 2013. Comorbidity and survival of Danish ovarian cancer patients from 2000–2011: a population-based cohort study. Clinical Epidemiology 5:57–63.
   PubMedGoogle Scholar
• Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF, Jaques DP. 2007. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. Journal of the American College of Surgeons 204:356–364.
   PubMed Web of Science ®Google Scholar
• Jiao YS, Gong TT, Wang YL, Wu QJ. 2015. Comorbidity and survival among women with ovarian cancer: evidence from prospective studies. Scientific Reports 5:11720.
   PubMed Web of Science ®Google Scholar
• Jorgensen TL, Teiblum S, Paludan M, Poulsen LO, Jorgensen AY, Bruun KH, et al. 2012. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecologic Oncology 127:367–374.
   PubMed Web of Science ®Google Scholar
• Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. 2015. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249–257.
   PubMed Web of Science ®Google Scholar
• Koppie TM, Serio AM, Vickers AJ, Vora K, Dalbagni G, Donat SM, et al. 2008. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 112:2384–2392.
   PubMed Web of Science ®Google Scholar
• Langstraat C, Aletti GD, Cliby WA. 2011. Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecologic Oncology 123:187–191.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. 1982. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 5:649–655.
   PubMed Web of Science ®Google Scholar
• Robbins JR, Gayar OH, Zaki M, Mahan M, Buekers T, Elshaikh MA. 2013. Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer. Gynecologic Oncology 131:593–597.
   PubMed Web of Science ®Google Scholar
• Sperling C, Noer MC, Christensen IJ, Nielsen ML, Lidegaard O, Hogdall C. 2013. Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database. Gynecologic Oncology 129:97–102.
   PubMed Web of Science ®Google Scholar
• Suidan RS, Leitao MM JR, Zivanovic O, Gardner GJ, Long Roche KC, Sonoda Y, et al. 2015. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecologic Oncology 138:246–251.
   PubMed Web of Science ®Google Scholar
• Tetsche MS, Dethlefsen C, Pedersen L, Sorensen HT, Norgaard M. 2008. The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer 8:31.
   PubMed Web of Science ®Google Scholar
• Tew WP, Fleming GF. 2015. Treatment of ovarian cancer in the older woman. Gynecologic Oncology 136:136–142.
   PubMed Web of Science ®Google Scholar
• Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ. 2011. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Gynecologic Oncology 118:537–547.
   Google Scholar
• Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. 2010. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 363:943–953.
   PubMed Web of Science ®Google Scholar